Function-based high-throughput screening for antibody antagonists and agonists against G protein-coupled receptors

Huanhuan Ren, Jian Li, Ning Zhang, Liaoyuan A. Hu, Yingli Ma, Philip Tagari, Jianqing Xu & Mei-Yun Zhang

Hybridoma and phage display are two powerful technologies for isolating target-specific monoclonal antibodies based on the binding. However, for complex membrane proteins, such as G protein-coupled receptors (GPCRs), binding-based screening rarely results in functional antibodies. Here we describe a function-based high-throughput screening method for quickly identifying antibody antagonists and agonists against GPCRs by combining glycosylphosphatidylinositol-anchored antibody cell display with β-arrestin recruitment-based cell sorting and screening. This method links antibody genotype with phenotype and is applicable to all GPCR targets. We validated this method by identifying a panel of antibody antagonists and an antibody agonist to the human apelin receptor from an immune antibody repertoire. In contrast, we obtained only neutral binders and antibody antagonists from the same repertoire by phage display, suggesting that the new approach described here is more efficient than traditional methods in isolating functional antibodies. This new method may create a new paradigm in antibody drug discovery.
The history of antibody drug discovery reflects the advancement of antibody screening technology. The invention of hybridoma technology in 1975 led to the first paradigm in antibody drug discovery. The first monoclonal antibody (mAb), muromonab-CD3 (OKT3), approved by FDA in 1986 was derived from hybridoma screening. The invention of recombinant DNA technology in the early 1970s allowed gene cloning and subsequently protein engineering for desired properties. The invention of polymerase chain reaction (PCR) in 1983 and phage display technology in 1985 further enabled batch amplification of antibody genes and isolation of target-specific binding antibodies from combinatorial antibody libraries in a high-throughput manner, which created a paradigm shift in antibody drug discovery. In 2002, adalimumab became the first phage display-derived antibody approved by FDA. It was also the first approved human mAb and is currently the best-selling antibody drug on the market. Phage display is now one of the most widely used technologies for antibody discovery and engineering. Following the invention of phage display technology, various other display technologies, such as yeast display and ribosome display, emerged, which further enhanced rapid discovery of antibodies. Compared to hybridoma technology that retains the natural paring of the heavy and light chains, display technologies allow random pairing of the heavy and light chains, which generates additional antibody diversity. Display technologies also facilitate generating antibodies against low immunogenic targets and engineering antibodies for desired properties. However, hybridoma screening and these display technologies are generally based on antibody binding to recombinant antigens. Following hybridoma screening and phage (or yeast, or ribosome) display, expression, and purification of isolated clones and characterization of purified antibodies for biofunction are mandatory. The workload for antibody production and characterization of isolated clones could be enormous, but the chance to obtain functional antibodies (antibody antagonists and agonists) may be slim.

G protein-coupled receptors (GPCRs) play important roles in many (patho)physiological processes and represent the largest family of drug targets. However, the conformation flexibility and low immunogenicity and antigenicity of GPCRs pose challenges to generating target-specific antibody binders, let alone functional antibodies against GPCRs. If the immunization was successful, hybridoma screening or phage-displayed library panning and screening may lead to the identification of neutral binders and, sometimes, antibody antagonists, but rarely antibody agonists. GPCR activation is a rather complex process. It involves a series of sequential conformational changes that are initiated by ligand engagement and coordinated by the transmembrane domains to eventually expose the G protein binding site in the intracellular side of the receptor. One-third of approved drugs target GPCRs, among which, only two are mAbs, Erenumab, and Mogamulizumab, and both were approved in 2018. Erenumab is a Calcitonin gene-related peptide (CGRP) receptor antagonist derived from XenoMouse immunization and hybridoma screening. Mogamulizumab is a humanized, defucosylated CCR4-binding mAb derived from mouse immunization and hybridoma screening. Mogamulizumab is a neutral binder and functions only in vivo through antibody-dependent cellular cytotoxicity for the treatment of adult T-cell leukemia-lymphoma. Ten GPCR-targeting mAbs are currently in clinical trials, among which, GMA102 is a humanized GLP-1R-binding mAb fused to GLP-1 peptide, and the rest are antibody antagonists or neutral binders conjugated to isotopes. None of these antibodies are antibody agonists. Due to the challenges to identifying antibody agonists to membrane receptors, it has been a common practice to use natural peptide ligands or ligand mimetics fused to Fc or other half-life extending moieties to agonize the receptors for the treatment of diseases. This approach may have the risk that the endogenous peptide ligand is wiped out by anti-drug neutralizing antibodies that may be induced by repeated administration of peptide ligand mimetics. Compared to natural peptide ligands and ligand mimetics, antibody agonist is preferred for its predictable pharmacokinetics and well-developed manufacturing process. Therefore, developing a function-based antibody high-throughput screening method would be of great value for identifying mAbs with desired biofunction to complex membrane protein targets.

We aim to develop a universal high-throughput screening method for direct identification of antibody antagonists and agonists to any GPCR targets of interest. We took advantage of glycosylphosphatidylinositol (GPI) anchoring system and β-arrestin recruitment-based reporter assay. GPI allows proteins, including antibodies, to anchor on the cell surface and keep the anchored proteins functional. More importantly, GPI anchoring sequences can be recognized by GPI transamidase for the attachment to the lipid rafts. GPIanchored proteins also preferentially diffuse to the lipid rafts for trafficking and signaling. The co-localization of GPCR targets and GPI-anchored antibodies in the lipid rafts would facilitate the interaction between the target and the anchored antibody on the same cell surface. β-arrestin recruitment upon ligand stimulation is a common phenomenon among GPCRs regardless of G protein-mediated downstream signaling pathways. GPI-anchored antibody library cell display in combination with β-arrestin recruitment-based reporter assay may be applied to isolating functional antibodies for any GPCR targets.

We validated this new method using human apelin receptor (APJ), a Gαi-coupled class A GPCR, as a model GPCR target. APJ is involved in cardiovascular function and agonizing APJ is beneficial for the treatment of chronic heart failure. APJ is also involved in angiogenesis and elevation of APJ level was observed in tumors. Therefore, APJ antibody antagonists may have the potential for the treatment of APJ-overexpressing tumors by inhibiting tumor angiogenesis. We previously immunized a camel with APJ nanodiscs and constructed an immune cameldel single domain antibody (sdAb) library in a phagemid vector. From the panning and screening of phage-displayed sdAb library against APJ liposomes, we obtained a panel of potent sdAb antagonists and a panel of neutral binders. No sdAb agonist was identified by the phage display effort. To validate the new method described in this study and to identify APJ antibody antagonists and agonists, we transfer the APJ immune sdAb library to a lentiviral vector containing decay accelerating factor (DAF) sequence for anchoring antibodies to GPI. We then transduce the recombinant lentivirus library into U2OS-derived Tango β-arrestin reporter cells stably expressing human APJ. Following β-arrestin recruitment-based cell sorting and screening, we identify a panel of sdAb antagonists with diverse epitope coverage and, for the first time to our knowledge, a potent sdAb agonist to human APJ.

Results

Proof of concept study and generation of a GPI-anchored sdAb library. Lentivirus transduction is widely used for generating stable cell lines. We constructed a lentiviral expression vector, designated pHBLV-puro-GPI, which contains a CMV promoter, a multiple cloning site (MCS), a his6 tag, (G4S)5 linker and DAF sequence (Supplementary Fig. 1a, b). Covalently linked DAF allows his-tagged sdAbs to anchor to GPI through a multiple cloning site (MCS). For a proof of concept (POC) study, we subcloned four sdAb genes to the pHBLV-puro-GPI vector,
including APJ neutral binding sdAb JN126, agonistic antibody-ligand fusion JN126P13, antagonistic sdAb JN241, and a control sdAb E3 recognizing an irrelevant GPCR. JN126 and JN241 are APJ sdAbs previously isolated from the APJ immune library by phage display, while JN126P13 is an antibody-ligand fusion with apelin 13 covalently linked to the C-terminus of the neutral binding sdAb JN126. Following the generation of recombinant lentivirus and the transduction of APJ stably expressing CHO-K1-derived PathHunter β-arrestin reporter cells, we measured antibody surface expression level by flow cytometry and tested the transduced cells for biological function by β-arrestin recruitment assay. The result from flow cytometry showed that all four tested sdAbs were highly expressed and well displayed on the cell surface. Treatment of these cells with phosphatidylinositol phospholipase C (PI-PLC) substantially reduced the surface density of these antibodies, confirming that they were indeed anchored to GPI (Supplementary Fig. 1c). In PathHunter β-arrestin assay, GPI-anchored sdAb JN241 and antibody-ligand fusion JN126P13 were confirmed to be antagonist and agonist, respectively, while neutral-binding sdAb JN126 and control sdAb E3 were non-functional (Supplementary Fig. 1d, e). We further tested their corresponding Fc fusions for GPI-anchored cell display. The results showed that sdAbs JN126 and JN241 fused to human Fc, JN126Fc and JN241Fc, and JN126Fc fused to apelin13, JN126FcP13, also well displayed on cell surface through GPI and kept their respective functional characteristics (Supplementary Fig. 1f-h).

PathHunter β-arrestin reporter assay system is suitable for monoclonal cell screening, but not suitable for sorting surface-displayed antibody cell library based on function because neither the fluorescent substrate for the reporter enzyme nor the product resides in the cells after the cells are washed. Therefore, we switched to the Tango β-arrestin assay system, in which both the fluorescent substrate and the product retain within the cells before and after hydrolysis by the β-lactamase reporter enzyme. We repeated the POC study with Tango/APJ β-arrestin reporter cells, in which APJ gene is stably integrated into the genome, as well as a transcription factor linked to the C-terminus of APJ through a tobacco etch virus (TEV) protease site. This reporter cell line also stably expresses a β-arrestin and TEV protease fusion protein. Upon ligand binding and receptor activation, β-arrestin-TEV fusion proteins are recruited to the intracellular side of the receptor, leading to the cleavage of transcription factor and subsequent expression of β-lactamase reporter gene that can be monitored by β-lactamase-mediated enzymatic reactions (Supplementary Fig. 2a). Results from the functional assay in Tango/APJ β-arrestin reporter cells confirmed that all four tested sdAbs behave the same as that in APJ PathHunter reporter cells (Fig. 1a and Supplementary data). Dot plots of JN241-expressing cells showed a clear gating window for the cells with antagonistic antibodies anchored on the cell surface (Fig. 1b and Supplementary data). Similarly, dot plots of JN126P13-expressing cells suggested a possible gating window for the cells with agonistic antibodies anchored on the cell surface (Fig. 1c and Supplementary data). To enrich for APJ-specific sdAb clones, we did one round panning of the phage-displayed immune library against 293FT/huAPJ cells, then bioassayed the inserts from the panned library to the lentiviral vector pHBLV-puro-GPI. We constructed a GPI-anchored sdAb library in pHBLV-puro-GPI with a size of 4 × 10^8 (10 fold larger than the panned phage library in size; Supplementary Fig. 2b). To bias the population toward a single sdAb per cell, we used a low multiplicity of infection of 0.3 in lentivirus transduction. Transduced cells account for 27% by flow cytometry 48 h post lentivirus infection. To eliminate non-transduced cells, 0.5 μg/ml puromycin was added to the cell-displayed sdAb library. Following the treatment with puromycin for a week, we carried out flow cytometry to determine the positive cell percentage and it reached 80% by staining the cells with anti-his antibody (Supplementary Fig. 2c).

**Function-based cell sorting and screening for sdAb antagonists.** Since we knew that sdAb antagonists exist in the immune repertoire, we first validated the function-based cell sorting and screening for APJ sdAb antagonists. Prior to the cell sorting, GPI-anchored sdAb library (1 × 10^8 cells, in total) was treated with 80% maximal effective concentration (EC50) of apelin 13 followed by substrate loading. Cells with low product intensity at 460 nm and high substrate intensity at 530 nm were sorted out (Fig. 2a and Supplementary data). Sorted cells were cultured and subjected to the second round of cell sorting. After three rounds of cell sorting, cells with antagonist activity were enriched based on the experimentally decreased ratio of product/substrate intensity (Fig. 2b and Supplementary data). Single cells from the third round sorted library were plated into 96-well plates and a total of 127 single-cell clones were subsequently tested for antagonist activity by β-arrestin recruitment assay. In all, 104 out of 127 cell clones showed higher than 20% inhibition. Among them, 72 clones showed higher than 50% inhibition (Fig. 2c and Supplementary data). Antibody genes from 24 positive cell clones with higher than 50% inhibitory activity were rescued by reverse transcription PCR (RT-PCR) and sequenced. Ten unique clones were obtained and further characterized. Soluble sdAbs of all 10 clones showed antagonist activity in APJ PathHunter assay. Seven sdAbs, JN400, JN402, JN406, and JN411-414, had a half-maximal inhibition concentration (IC50) below 200 nM. Two sdAbs, JN401 and JN409, showed an IC50 over 200 nM (Fig. 2d and Supplementary data). One sdAb JN404 showed weak antagonist activity and the IC50 was not determined. We did a correlation analysis between the percentage inhibition of the cell clones and the IC50 of the nine sdAbs isolated from the corresponding cell clones. Notably, the percentage inhibition of a cell clone correlates well with the IC50 of soluble sdAb isolated from the corresponding cell clone (Fig. 2e and Supplementary data).

**Sequence and epitope comparison of isolated APJ sdAb antagonists.** We further tested the isolated sdAb antagonists for antagonist activity by LANCE CAMP assay as previously described. The IC50s obtained by the CAMP assay correlate with those by the β-arrestin recruitment assay (Fig. 3a, b and Supplementary data). We next compared the ten sdAb antagonists isolated by function-based cell sorting and screening with the sdAb antagonists previously isolated by phage display from the same immune repertoire (Supplementary Fig. 3). Sequence comparison showed that one of the sdAb antagonists, JN414, shares the same sequence and epitope binding involves either ECL2 (group 1) or ECL1 (group 3), or

**Opioid Receptor (DOR)**
Supplementary data). Single cells from the 3rd round sorted library were grown out and a total of 72 cell clones were screened by Tango/APJ -arrestin assay at antagonist (b) or agonist (c) mode. The gated window and the percentage of gated cell population are shown. In the assay at antagonist mode, apelin 13 at EC80 dose was added to the plates. Antibody antagonists negatively affect apelin 13 binding to the receptor, which causes decreased β-lactamase production and subsequent reduced substrate hydrolysis, leading to more substrate fluorescence (at 530 nm) and less product fluorescence (at 460 nm). In the assay at agonist mode, no ligand was added to the plates.

**Fig. 1 POC study in U2OS/APJ β-arrestin reporter cell line. a** Flow cytometry of Tango/APJ β-arrestin assay cells transduced with recombinant lentivirus containing the genes encoding sdAb E3, or JN241, or JN126P3. **b, c** Flow cytometry of Tango/APJ β-arrestin assay cells following β-arrestin recruitment assay at antagonist (b) or agonist (c) mode. The gated window and the percentage of gated cell population are shown. In the assay at antagonist mode, apelin 13 at EC80 dose was added to the plates. Antibody antagonists negatively affect apelin 13 binding to the receptor, which causes decreased β-lactamase production and subsequent reduced substrate hydrolysis, leading to more substrate fluorescence (at 530 nm) and less product fluorescence (at 460 nm). In the assay at agonist mode, no ligand was added to the plates.

both (group 2). The remaining two groups with moderate to weak antagonist activities bound to the N-terminus and almost all three extracellular loops of APJ (group 4 and 5), indicating that they are more sensitive to the conformation integrity of the receptor (Fig. 3 and Supplementary data).

**Discussion**

This study describes a new approach for efficient identification of antibody antagonists and agonists against GPCRs by combining GPI-anchored antibody cell surface display with β-arrestin-mediated receptor agonism.
recruitment reporter assay. This new method directly links antibody genotype with phenotype, allowing quick identification of functional antibodies. Compared to binding-based screening methods, such as hybridoma screening and phage display, this function-based high-throughput screening method decreases the screening scale and minimizes the workload for hits identification. The GPI-anchoring system may be advantageous over covalent linking the antibodies to a transmembrane domain in autocrine signaling-based cell sorting and screening\textsuperscript{13,44}. The colocalization of GPI and GPCRs in lipid rafts facilitates GPI-anchored antibody interactions with the GPCR target\textsuperscript{24,27}. Furthermore, soluble antibodies can be obtained by directly digesting GPI-anchored antibodies with PI-PLC for a quick confirmation of biofunction prior to antibody gene amplification and subcloning, which can further minimize the workload and speed up the process for the identification of functional antibodies. We used β-arrestin recruitment-based cell sorting and screening instead of monitoring G protein-based signaling. The advantage of β-arrestin recruitment-based cell sorting and screening is that it does not depend on knowledge of the G protein signaling specificity of the target receptor. β-arrestin recruitment upon receptor activation is a common pathway among GPCRs, so this new method can be used to identify antibody antagonists and, more importantly, antibody agonists to any GPCR targets.

We validated this method by using APJ as a model GPCR target and identified a panel of APJ sdAb antagonists with diverse epitopes and, for the first time, to our knowledge, an sdAb agonist from an immune sdAb library. We previously isolated a panel of potent APJ sdAb antagonists and non-functional binders from the same immune library by phage display, but we were not able to isolate any sdAb agonists from the library by phage display. Phage display panning seems to enrich for high-affinity binders to the dominant epitopes of the antigen. Epitope localization studies suggest that phage display-derived sdAb antagonists and non-functional binders dominantly bind to the ECL2 and the N-terminus of APJ, respectively. APJ ECL2 is critical for ligand binding and plays an important role in mediating ligand-induced receptor activation. It is understandable that the binding of sdAbs to ECL2 blocks the binding of apelin 13 to the ligand binding pocket, resulting in competitive antagonist activity, while the binding of sdAbs to the N-terminus does not affect the ligand binding. Unlike binding-based panning and screening of phage-displayed antibody library, function-based cell sorting of GPI-anchored antibody library described in this study facilitated the isolation of target-specific antibody antagonists that bind to diverse epitopes and have a broad range of antagonist activity. Most likely, function-based sorting of single antibody-displayed cells does not generate a pressure on cells to compete for the receptor, unlike the panning of phage-displayed antibody library, in which binders compete for a limited amount of antigen proteins. More importantly, the potency of isolated sdAb antagonists correlates with the inhibitory activity of the corresponding cell clones in the Tango/APJ β-arrestin assay. Therefore, one can isolate antibody antagonists with desired (high, moderate, or low) potency based on the inhibitory activity of the cell clones. Antibody agonists to GPCRs are rare, but the new method described in this study allows us to successfully identify the potent sdAb agonist [JN300 to human APJ].

We described here the cell surface display of cameld sdAb libraries by anchoring them to GPI. In this study, we also tested sdAb-Fc fusions for anchoring to GPI and found that GPI-anchored sdAb-Fcs display well on cell surface and retain their
biological functions, suggesting that Fab or IgG libraries could also be anchored to GPI for cell surface display and for function-based cell sorting and screening. To transfer a large phage-displayed antibody library to a lentiviral vector, library size might be a concern. We used one round of phage library panning prior to the transfer to enrich the binders without losing diversity. The introduction of the one round of binding-based phage library panning may lead to the possible loss of agonistic clones, which partially explains why we identified only one sdAb agonist in this campaign. In addition, we noticed that constitutive activation of the cells by GPI-anchored agonist antibodies led to the loss of agonist antibody genes in the cells or even cell apoptosis, which results in the failure in recovering the agonist sdAb genes following function-based cell sorting and screening. It is also possible that the cells were activated by agonist antibodies displayed by the neighbor cells when the cell density was high during sorting, which may lead to false positive signal. Inducible expression of GPI-anchored antibodies may alleviate this negative effect and enhance the sorting and screening efficiency in isolating agonist antibodies.

APJ functional antibodies identified in this study may have the potential for antibody therapeutics. To our knowledge, APJ sdAb agonist JN300 is the first antibody agonist identified so far against class A GPCRs, the largest and most important GPCR family for drug discovery. JN300 may have the therapeutic potential for the treatment of chronic heart failure. Since APJ is also involved in angiogenesis and elevated APJ was observed in solid tumors, the APJ sdAb antibodies identified in this study may have the potential to treat solid tumors by blocking tumor angiogenesis. This function-based antibody high-throughput screening method can be applied to all GPCR targets. It can also be adapted to isolating functional antibodies against non-GPCRs by using reporter gene assays monitoring the downstream signaling pathways. We believe that the new method described here will greatly facilitate the identification of GPCR functional antibodies with therapeutic potentials, which may create a new paradigm for antibody therapeutics.

Methods

Cell lines and culture media. Unless otherwise specified, all cell lines and culture reagents were from Invitrogen. HEK293FT cell was maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS, 100 U per ml penicillin, 100 µg per ml streptomycin, 0.1 mM non-essential amino acids (NEAA), 1 mM sodium pyruvate. HEK293FT/huAPJ cell line, HEK293FT/huAPJ domain-swapped mutants, and HEK293FT/huSSTR2 cell line were in-house generated by lipofection in HEK293FT cell culture medium containing 1.5 µg per ml puromycin. PathHunter CHO-k1/APJ β-arrestin cell line was obtained from DiscoverX and maintained in DMEM/F12 medium supplemented with 10% FBS, 100 U per ml penicillin, 100 µg per ml streptomycin, 500 µg per ml geneticin, and 300 µg per ml hygromycin B. CHO-k1/APJ β-arrestin cells with GPI-anchored sdAbs were in-house generated and maintained in PathHunter cell culture medium containing 5 µg per ml puromycin. U2OS AGTR1 (APJ)
We modified pHBLV-puro vector by inserting a signal peptide right after the CMV promoter, and a his6 tag, a (G4S)5 linker and a GPI attachment signal sequence, the C-terminal 34 amino acid residues of DAF, after the MCS. The modified lentiviral vector was designated pHBLV-puro-GPI. Recombinant sdAbs or sdAb-Fc genes were synthesized by GenScript (Nanjing, China) and cloned into pHBLV-puro-GPI vector via pMD2.G using Lipofectamine 2000 (Invitrogen) as transfection reagent.

Stable cell line used in receptor internalization assay was purchased from DiscoverX (Cat. 93-0710C3) and maintained in AssayComplete Cell Culture Kit 103 (DiscoverX) with 0.25 μg per ml puromycin, 250 μg per ml hygromycin B and 500 μg per ml geneticin. FreeStyle 293F cell line was maintained in FreeStyle 293 expression medium. Tango/APJ β-arrestin assay cell line was maintained in McCoy’s 5A medium (modified) with 10% dialyzed FBS, 0.1 mM NEAA, 100 U per ml penicillin, 100 μg per ml streptomycin, 1 mM sodium pyruvate, 25 mM HEPES (pH 7.3), 200 μg per ml zeocin, 50 μg per ml hygromycin B, and 100 μg per ml geneticin. Tango/APJ β-arrestin assay cells with GPI-anchored sdAbs were house-generated and maintained in Tango/APJ β-arrestin assay cell culture medium containing 0.5 μg per ml puromycin. All cells were maintained in 5% CO2 incubators with a humidified atmosphere at 37 °C.

**Plasmids.** A pHEN2-based phagemid vector was used in the construction of camelid immune sdAb library. The third-generation lentiviral transfer vector pHBLV-puro, lentiviral packaging vector psPAX2 and envelope vector pMD2.G were purchased from Han bio, China. pHBLV-puro vector contains a CMV promoter upstream a multiple cloning site (MCS). We modified pHBLV-puro vector by inserting a signal peptide right after the CMV promoter, and a his6 tag, a (G4S)5 linker and a GPI attachment signal sequence, the C-terminal 34 amino acid residues of DAF, after the MCS. The modified lentiviral vector was designated pHBLV-puro-GPI. Recombinant sdAbs or sdAb-Fc genes were synthesized by GenScript (Nanjing, China) and cloned into pHBLV-puro-GPI vector via Sph I and Nhe I sites.

**Generation of recombinant lentiviruses.** All lentivirus-related experiments were performed at BSL2 lab. Briefly, 5 × 10^6 HEK293FT cells were seeded in 10 ml of growth medium in a 10-cm cell culture dish. After cultivation for 18–24 h, cells were transfected with 5 μg of pHBLV-puro-GPI plasmid, 10 μg of psPAX2 plasmid, and 5 μg of pMD2.G using Lipofofectamine 2000 (Invitrogen) as transfection reagent.

Following incubation for 16 h, culture supernatant was removed and replaced with 10 ml fresh growth medium containing 10 mM sodium butyrate (Sigma). Following further incubation for 8 h, the medium was changed to growth medium again, and cells were incubated for 24 h. The culture supernatants were then harvested and concentrated by using PEG-it Virus Precipitation Solution (System Biosciences) according to the manufacturer’s instructions. The concentrated viruses were aliquoted and stored at −80 °C.

**Titrination of recombinant lentiviruses.** The recombinant lentiviruses were titrated in HEK293FT cells. Briefly, 1 × 10^5 cells in 500 μl cell culture medium were seeded into each well in a 12-well plate. After overnight cultivation, 500 μl of 10-fold serial diluted recombinant lentiviruses were added to each well for virus transduction. After cultivated at 37 °C for 48–72 h, the expression level of the transduced gene was measured by flow cytometry. The virus transducing units (TU) were calculated according to the formula: TU per ml = cell number × positive cell population %/virus volume × dilution fold.

**Generation of stably transduced cells for POC study.** To generate stably transduced cell lines, 1 × 10^6 CHO-K1/APJ or 2 × 10^7 Tango/APJ β-arrestin cells per well were seeded onto a 12-well plate. After overnight cultivation, 500 μl of 10-fold serial diluted recombinant lentiviruses were added to each well for virus transduction. After cultivated at 37 °C for 48–72 h, the expression level of the transduced gene was measured by flow cytometry. The virus transducing units (TU) were calculated according to the formula: TU per ml = cell number × positive cell population %/virus volume × dilution fold.

**Flow cytometry.** To test the expression level of transduced genes, 2 × 10^5 lentivirus transduced cells were collected, washed twice with 1X PBS, and incubated with a

---

**Fig. 4 Function-based cell sorting and screening for agonistic cell clones.** a Dot-plot of Tango/APJ sdAb cell-displayed library following substrate loading. Cells with high ratio of product/substrate (460 nm/530 nm) were sorted out. The gating window and the percent of gated cell population in the 3rd round cell sorting are shown. b β-arrestin recruitment activity of the parental library and the 1st, 2nd and 3rd round sorted cell populations by Tango/APJ β-arrestin assay. Data are expressed as mean with SD. Statistical analysis was done using unpaired two-tailed t test. The higher product/substrate ratio, the higher agonist activity. c Percentage activation of monoclonal cells by Tango/APJ β-arrestin assay cells treated with 15 nM apelin 13. Two representative single-cell clones, 9E10 and 4C6, are shown. A scale bar of 250 μm is shown in each image.
mouse anti-his antibody (1 μg per ml, GenScript, A00186) at 4 °C for 1 h. Cells were then washed twice with 1X PBS, and stained with Alexa Fluor 488 conjugated goat anti-mouse antibodies (2 μg per ml, Invitrogen, A-11029) at 4 °C for 30 min. After that, cells were washed twice with 1X PBS again and resuspended in 60 μl 1X PBS. FACs analysis was performed in an InteliCyt (Que Sceener (Sartorius)). In the PI-PLC treatment experiment, 5 × 10⁴ transduced CHO-k1-huAPJ cells were treated with 0.2 units of PI-PLC (Invitrogen, P-6466) or 1X PBS and rocked at 4 °C for 30 min. The ratio of the GeoMean with sdAb staining relative to the highest GeoMean with anti-HA antibody staining was calculated as the GeoMean with sdAb staining relative to the GeoMean with anti-HA antibody staining. All the ratios were normalized to the binding activity of the VHH genes by RT-PCR and cDNA cloning and plated each serial dilution onto 2YTCG (50 μg per ml Carbenicillin, 2% glucose) plates for phage titration. The output of phage library was 4 × 10⁶. All the phage-infected TG1 cells were plated onto a Nunc square bioassay dish and incubated at 30 °C overnight. Bacteria were scraped off from the dish and amplified for phagelike preparation. At this step, the bacterial inoculum should be at least 10-fold of the phage output and the OD₅₉₀ value of the amplified bacteria should be <3.0. A total of 875 ng of digested and gel-extracted inserts were ligated with 5 μg of digested and purified lentiviral vector pHBLV-puro-GPI using Spl I and Nhe I sites. The ligation product was used to transform electrocompetent E. coli. strain Sbl3 (Huayueyang Bio, Beijing, China), resulting in a combinatorial lentiviral sdAb library with a size of 4 × 10⁷ individual clones. The combinatorial lentiviral sdAb library was packaged into lentiviruses as described above. A total of 3.5 × 10⁸ Tango/APJ β-arestin assay cells from 35 dishes (15-cm dish, 1 × 10⁷ cells per dish) were then used in the transduction with recombinant lentiviruses at multiplicity of infection of 0.3. The GPI-anchored sdAb cell-displayed library size was defined as the number of his 6 tag-positive cells measured by flow cytometry 48 h post infection. In this practice, his 6 tag-positive cells were on average 27% in each dish, so the actual library size in mammalian cells was 9.45 × 10⁷. The non-transduced cells were eliminated by the treatment with 0.5 μg per ml puromycin.

**cAMP assay.** Cellular cAMP was measured by Lance Ultra cAMP kit (Perkin Elmer) according to manufacturer’s instruction. Briefly, 2000 cells in 10 μl assay buffer (HBSS + 5 mM HEPES + 0.1% BSA) were added into each well on a 96-half well assay plate and stimulated with test antibodies (at agonist mode), or with apelin 13 ligand at EC₅₀ close together with test antibodies (at antagonist mode) in the presence of 2.5 μM forskolin. The plates were incubated at 37 °C for 30 min followed by the addition of 10 μl of 4X Eu-CAMP and 10 μl of 4X Uligh-Anti-cAMP working solutions. The mixture was incubated at room temperature for 60 min and then read.
with Enviplate reader using a recommended setting (Excitation at 320 nm and Emission at 460 nm). The cellular cAMP level was expressed as the signal ratio of Em460 nm to Em530 nm. In all, 100 nM apelin 13 was used as a positive control and 1% DMSO as a negative control on each plate.

**PathHunter β-arrestin recruitment assay.** The PathHunter β-arrestin recruitment assay was performed according to manufacturer's instructions with minor modifications. Briefly, cells were seeded on 384-well plates (Corning, #3707) at 5000 cells per well in 1X FBS and cultivated overnight. On the next day, test antibodies (at agonist mode) or apelin 13 ligand at EC50 dose (at antagonist mode) were added to the wells. After incubation at 37 °C for 1.5 h, detection reagent was added to each well. The mixture was incubated at room temperature for 60 min before reading with a luminance plate reader (Envision or CLARIOstar).

**PathHunter-based GPCR internalization assay.** The PathHunter-based GPCR internalization assay was performed according to manufacturer’s instructions with minor modifications. Briefly, U2OS cells stably expressing human API were seeded on 384-well plates (Corning, #3707) at 5000 cells per well in Opti-MEM with 0.5% FBS and incubated for 24 h. On the second day, serially diluted antibodies were added into each well. After incubation at 37 °C for 3 h, detection reagent was added to each well. The mixture was incubated at room temperature for 60 min before reading with a luminance plate reader (Envision or CLARIOstar).

**Tango assay with GPl-anchored sdAbs.** Briefly, parental cells or sdAb-anchored cells were seeded on 96-well plates (costar, #3605) at 50,000 cells per well in 40 μl FreeStyle 293 expression medium and cultivated for 48 h. On the third day, 10 μl FreeStyle 293 expression medium containing apelin 13 at EC50 dose (at antagonist mode) were added to the plates. Parental cells treated with 100 nM apelin 13 or 0.1% DMSO were used as positive or negative controls, respectively. After incubation at 37 °C for 5 h, 10 μl of LIVEBLAZER FRET/B loading solution was added to the wells. The mixture was incubated at room temperature for 2 h before reading with a fluorescence plate reader (CLARIOstar, Excitation at 405 nm, Emission at 460 nm and 530 nm) or analyzed by a recommended setting (Excitation at 320 nm and Emission at 460 nm to 530 nm) or analyzed by a luminance Plate reader (Envision or CLARIOstar). The mixture was incubated at room temperature for 60 min before reading with a luminance plate reader (Envision or CLARIOstar).

**Function-based cell sorting and screening.** The GPl-anchored sdAb library in FreeStyle 293 expression medium was plated onto four to five 15-cm cell culture dishes and cultivated for 48 h in 5% CO2 incubator at 37 °C for cell starvation. Total his-positive cell number should larger than the 10-fold size of panned-phae library.

For cell sorting at agonist mode, one-fifth volume of substrate solution was added to the cells on the third day. The cells were then incubated at room temperature for 2 h, followed by digestion with 0.05% Trypsin-EDTA solution (Invitrogen) and then washed three times with 1X PBS. Ressuspended cells in 1X PBS supplemented with 2% BSA were sorted for the cells with high signal ratio of Em460 nm to Em530 nm using FACSSz Jazz Cell Sorter (BD Biosciences). For cell sorting at antagonist mode, on the third day, cells medium was replaced with fresh FreeStyle 293 expression medium containing apelin 13 at EC50 dose and cultivated at 37 °C for 12–16 h. On the fourth day, one-fifth volume of substrate solution were added to the plates. The mixture was incubated at RT for 2 h for substrate loading. After cell digestion and washing, cells with low signal ratio of Em460 nm/Em530 nm were sorted out.

Following the 3rd round sorting, single cell clones were seeded to 96-well assay plates (Corning, #3603). When the single cells grow to over 50% confluence, the culture medium was replaced with FreeStyle 293 expression medium and cells were incubated for 48 h at 37 °C. The Tango assay was then performed as described above. Positive clones were double checked under a fluorescent microscope (LEICA DMi8, Excitation at 409 nm). Antibody genes were recovered by one-step RT-PCR using a forward primer (5'-CTGCTGGGAATGCCTGG-TG-3') and a reverse primer (5'-GGTGGTGATGACATGTGCTCC-3') and cloned into a TA cloning vector for sequencing.

**Antibody expression and purification.** Soluble sdAbs were expressed in FreeStyle 293 transient expression system (Invitrogen) using pTT5 vector. Briefly, 3 x 10^7 FreeStyle 293 F cells were transfected with 30 μg of pTT5 plasmid by polyethyleneimine. After cultivation at 37 °C for 3–6 days, the culture supernatants were harvested for sdAb purification. His-tagged soluble sdAbs were purified by immobilized metal affinity chromatography (IMAC) as follow: 10 mM imidazole and 300 mM NaCl (final concentration) was added to the supernatant. The supernatant was then mixed with pre-washed Ni-NTA resin (Qiagen) (0.2 ml resin per 30 ml culture) and incubated at 4 °C for 1 h. The resin was washed with 5 column volume (CV) of 1X PBS containing 20 mM imidazole. Bound sdAbs were eluted by 3 CV of elution buffer (1X PBS supplemented with 300 mM imidazole) and the eluates dialyzed against 1X PBS to remove imidazole. Antibody concentration was measured by Nanodrop (E = 28, MW = 15.5) or BCA assay (Pierce™ BCA Protein Assay Reagent, microplate mode).

**Statistics and reproducibility.** Each sample was tested in duplicate or triplicate in functional assays and each functional assay was repeated twice using the same samples. Representative data were shown. Statistical analysis was done using GraphPad Prism 7 software. Unpaired two-tailed t test was used to determine the statistical differences between different samples. Pearson correlation analysis (linear regression) was used to examine the association between experimental variables. P value below 0.05 is considered as statistically significant for either test.

**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability**

All data needed to evaluate the conclusions in the paper are present in the paper. Additional data and research materials related to this paper are available upon reasonable request by contacting the corresponding authors of this paper.

Received: 24 October 2019; Accepted: 2 March 2020; Published online: 26 March 2020

References

1. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
2. Reichert, J. M. Marketed therapeutic antibodies compendium. mAbs 4, 413–415 (2012).
3. Jackson, D. A., Symons, R. H. & Berg, P. Biochemical method for inserting new genetic information into DNA of Simian Virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc. Natl Acad. Sci. USA 69, 2904–2999 (1972).
4. Cohen, S. N., Chang, A. C., Boyer, H. W. & Helling, R. B. Construction of biologically functional bacterial plasmids in vitro. Proc. Natl Acad. Sci. USA 70, 3240–3244 (1973).
5. Berg, P. et al. Letter: potential biohazards of recombinant DNA molecules. Science 185, 303 (1974).
6. Heyneker, H. L. et al. Synthetic lac operon DNA is functional in vivo. Nature 263, 748–752 (1976).
7. Morrow, J. F. et al. Replication and transcription of eukaryotic DNA in Escherichia coli. Proc. Natl Acad. Sci. USA 71, 1743–1747 (1974).
8. Mullis, K. et al. Specific enzyme amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harb. Symp. Quant. Biol. 51, Pt 1, 263–273 (1986).
9. Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315–1317 (1985).
10. Lorenz, H. M. Technology evaluation: adalimumab, Abbott laboratories. Curr. Opin. Mol. Ther. 4, 185–190 (2002).
11. Lindsey, C. W. Predictions and statistics for the best-selling drugs globally and in the United States in 2018 and a look forward to 2024 projections. ACS Chem. Neurosci. 10, 1115 (2019).
12. Kaleli, N. E., Karadag, M. & Kalyoncu, S. Phage display derived therapeutic antibodies have enriched aliphatic content: insights for developability issues. Proteins 87, 607–619 (2018).
13. Boder, E. T. & Wittrup, K. D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553–557 (1997).
14. Hanes, J. & Plückthun, A. In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl Acad. Sci. USA 94, 4937–4942 (1997).
15. Pyke, C. et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155, 1280–1290 (2014).
16. Ravn, P. et al. Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinoptropic polypeptide receptor. J. Biol. Chem. 288, 19760–19772 (2013).
17. Siriram, K. & Insel, P. A. G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs? Mol. Pharmacol. 93, 251–258 (2018).
18. Hauser, A. S., Atwood, M. M., Rask-Andersen, M., Schioth, H. B. & Gloriam, D. E. Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. 16, 829–842 (2017).
19. Dolgin, E. First GPCR-directed antibody passes approval milestone. Nat. Rev. Drug Discov. 17, 457–459 (2018).
20. Mullard, A. FDA approves second GPCR-targeted antibody. Nat. Rev. Drug Discov. 17, 613 (2018).
21. Shi, L. et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J. Pharmacol. Exp. Ther. 356, 223–231 (2016).
22. Niwa, R. et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 64, 2127–2133 (2004).
23. Verhelst, D. et al. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 363, 1768–1771 (2004).
24. Wen, M. et al. GPI-anchored single chain Fv—an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike. Retrovirology 7, 79 (2010).
25. Liu, L. et al. Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitor. J. Virol. 87, 1899–1905 (2013).
26. Liu, L. et al. The glycosylphosphatidylinositol-anchored variable region of llama heavy chain-only antibody JM4 efficiently blocks both cell-free and T-cell-T cell transmission of human immunodeficiency virus type 1. J. Virol. 90, 10642–10659 (2016).
27. Kinoshita, T. & Fujita, M. Biosynthesis of GPI-anchored proteins: special emphasis on GPI lipid remodeling. J. Lipid Res. 57, 6–24 (2016).
28. Villar, V. A., Cuevas, S., Zheng, X. & Jose, P. A. Localization and signaling of GPCRs in lipid rafts. Methods Cell Biol. 132, 3–23 (2016).
29. Fallahi-Sichani, M. & Lindermayer, J. J. Lipid raft-mediated regulation of G-protein coupled receptor signaling by ligands which influence receptor dimerization: a computational study. PLoS ONE 4, e6604 (2009).
30. Barnett-Norris, J., Lynch, D. & Reggio, P. H. Lipids, lipid rafts and caveolae: their importance for GPCR signaling and their centrality to the endocannabinoid system. J. Lipid Res. 77, 1625–1639 (2005).
31. Syrovatkina, V., Alegre, K. O., Dey, R. & Huang, X. Y. Regulation, signaling, and physiological functions of G-proteins. J. Mol. Biol. 428, 3850–3868 (2016).
32. Ashley, E. A. et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc. Res. 65, 73–82 (2005).
33. Japp, A. G. & Newby, D. E. The apelin-APJ system in heart failure: pathophysiological relevance and therapeutic potential. Biochem. Pharmacol. 75, 1882–1892 (2008).
34. Japp, A. G. et al. Vascular effects of apelin in vivo in man. J. Am. Coll. Cardiol. 52, 908–913 (2008).
35. Wu, L., Chen, L. & Li, L. Apelin/APJ system: a novel promising therapy target for pathological angiogenesis. Clin. Chim. Acta 466, 78–84 (2017).
36. Muto, J. et al. The apelin-APJ system induces tumor angiogenesis in hepatocellular carcinoma. Anticancer Res. 34, 5313–5320 (2014).
37. Berta, J. et al. Apelin promotes lymphangiogenesis and lymph node metastasis. Oncotarget 5, 4426–4437 (2014).
38. Kalin, R. E. et al. Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. Dev. Biol. 305, 599–614 (2007).
39. Ma, Y. et al. Structure-guided discovery of a single-domain antibody agonist of human apelin receptor. Sci. Adv. 6, eaax7379 (2020).
40. Zlokarnik, G. et al. Quantification of transcription and clonal selection of single living cells with beta-lactamase as reporter. Science 279, 84–88 (1998).
41. Kunapuli, P. et al. Development of an intact cell reporter gene beta-lactamase assay for G protein-coupled receptors for high-throughput screening. Anal. Biochem. 314, 16–29 (2003).
42. Ban, T. et al. GPCR structure and function relationship: identification of a biased apelin receptor mutant. Biochem. J. 475, 3813–3826 (2018).

Acknowledgements
We thank M. Zhang for supporting this study and for insightful discussions, X. Ma and Y. Song for helpful discussions, and I. Chen and M. Michaels for critical reading of the manuscript. The study was funded by Amgen Inc. and partially by a grant from Shanghai Pudong New Area Technology Development Postdoctoral Fund. H.R. was a postdoc fellow at the time the research was conducted.

Author contributions
H.R. performed all experiments, analyzed the data, and drafted the manuscript. J.L. did preliminary test with Tango/APJ β-arrestin assay cells and provided important suggestions. N.Z. generated stable cell pools of APJ and DOR domain-swapped mutants for epitope localization. L.A.H. and Y.M. assisted in data interpretation and manuscript preparation. P.T. supported this study and provided valuable suggestions. J.X. co-supervised the study, assisted in data interpretation and manuscript preparation. M.-Y.Z. conceived and supervised the project, designed experiments, reviewed data, and wrote the paper.

Competing interests
H.R., J.L., N.Z., L.A.H., Y.M., P.T., and M.-Y.Z. are employees of Amgen.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s42003-020-0867-7.

Correspondence and requests for materials should be addressed to M.-Y.Z. or J.X.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.